![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » UK Launches New Trial Platform to Accelerate COVID-19 Treatments
UK Launches New Trial Platform to Accelerate COVID-19 Treatments
![UKflag.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/UKflag.jpg?t=1586293848&width=430)
July 9, 2020
The UK has launched a new clinical trial platform aimed at accelerating the development of COVID-19 treatments.
The AGILE initiative will test promising treatments in COVID-19 patients to see if they should be fast-tracked to large-scale trials. The trial platform was created by the University of Liverpool’s School of Tropical Medicine and the Southampton Clinical Trials Unit.
Ridgeback Biotherapeutics’ investigational antiviral EIDD-2801 will be the first treatment evaluated.
Upcoming Events
-
21Oct